A Second Manufacturer Just Told Nevada Not to Use its Drugs for Executions

The state’s deputy solicitor general called the move “ironic.”

Hailshadow/Getty

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Another pharmaceutical company doesn’t want Nevada to use its drug to execute Scott Dozier. On Monday, a district judge approved a motion filed by Hikma, the manufacturer of the powerful opioid fentanyl, to join the lawsuit filed by Alvogen, the maker of the controversial sedative midazolam. Midazolam has been blamed for several botched executions in the past and was going to be part of a three-drug combination used to execute Dozier. His scheduled execution in July was put on hold after Alvogen filed suit. 

Hikma is arguing that the company specifically told Nevada in 2016 that its drugs could not be used for an execution. Alvogen made similar claims in its lawsuit, accusing the state of secretly obtaining the drug despite the company’s warnings that it does not approve of the use of its drugs for lethal injections. The third component of Nevada’s three-drug protocol is a muscle paralyzer that medical professionals said could mask the inmate’s pain during an execution.

Dozier has been on death row since 2007 for the 2002 murder of Jeremiah Miller. Beginning in 2016, he gave up any effort to appeal his sentence, and maintained that he wanted to be put to death. Just hours before Dozier was set to die on July 11, a district judge issued a temporary restraining order blocking the state from using the midazolam. In response, Nevada filed a petition with the Nevada Supreme Court, asking that the decision that halted the execution be thrown out and accusing Alvogen of mounting a public relations campaign. “[Alvogen] filed this lawsuit to salvage its image and shift the blame to the State for Alvogen’s failure to impose the controls that it was touting to anti-death penalty advocates,” the petition says. The state Supreme Court is now considering the petition.

Nevada now has to contend with yet another manufacturer and in response leveled similarly harsh criticism for Hikma, implying that it was attempting to distract attention from a far bigger problem. The deputy solicitor general called it “ironic that the maker of fentanyl, which is at the center of the nation’s opioid crisis and is responsible for illegal overdoses every day is going to…claim reputational injury from being associated with a lawful execution.” 

But some states still plan to use these drugs. Carey Moore, who is set to die in Nebraska on August 14, will likely now be the first person executed with the powerful painkiller. The state intends to use the opioid in a four-drug protocol to execute the inmate, who shot and killed Maynard Helgeland and Reuel Van Ness five days apart in 1979. Nebraska has come under fire for refusing to disclose where its lethal injection drugs came from despite court orders to do so. 

Assuming that the drugs were manufactured by Pfizer, Independent Nebraska state Sen. Ernie Chambers, a long time anti-death penalty advocateurged the company to follow in Alvogen’s footsteps and sue the state in order to have the drugs returned and the execution halted. But the company said it had no records of Nebraska obtaining restricted drugs and was not going to file a lawsuit. “So where did the governor get his drugs?” Chambers wrote on Facebook after Pfizer declined to sue the state. “He’s not saying, and he’s refusing to obey the courts who have ordered him to share the information.”

WE'LL BE BLUNT.

We have a considerable $390,000 gap in our online fundraising budget that we have to close by June 30. There is no wiggle room, we've already cut everything we can, and we urgently need more readers to pitch in—especially from this specific blurb you're reading right now.

We'll also be quite transparent and level-headed with you about this.

In "News Never Pays," our fearless CEO, Monika Bauerlein, connects the dots on several concerning media trends that, taken together, expose the fallacy behind the tragic state of journalism right now: That the marketplace will take care of providing the free and independent press citizens in a democracy need, and the Next New Thing to invest millions in will fix the problem. Bottom line: Journalism that serves the people needs the support of the people. That's the Next New Thing.

And it's what MoJo and our community of readers have been doing for 47 years now.

But staying afloat is harder than ever.

In "This Is Not a Crisis. It's The New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, why this moment is particularly urgent, and how we can best communicate that without screaming OMG PLEASE HELP over and over. We also touch on our history and how our nonprofit model makes Mother Jones different than most of the news out there: Letting us go deep, focus on underreported beats, and bring unique perspectives to the day's news.

You're here for reporting like that, not fundraising, but one cannot exist without the other, and it's vitally important that we hit our intimidating $390,000 number in online donations by June 30.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. It's going to be a nail-biter, and we really need to see donations from this specific ask coming in strong if we're going to get there.

payment methods

WE'LL BE BLUNT.

We have a considerable $390,000 gap in our online fundraising budget that we have to close by June 30. There is no wiggle room, we've already cut everything we can, and we urgently need more readers to pitch in—especially from this specific blurb you're reading right now.

We'll also be quite transparent and level-headed with you about this.

In "News Never Pays," our fearless CEO, Monika Bauerlein, connects the dots on several concerning media trends that, taken together, expose the fallacy behind the tragic state of journalism right now: That the marketplace will take care of providing the free and independent press citizens in a democracy need, and the Next New Thing to invest millions in will fix the problem. Bottom line: Journalism that serves the people needs the support of the people. That's the Next New Thing.

And it's what MoJo and our community of readers have been doing for 47 years now.

But staying afloat is harder than ever.

In "This Is Not a Crisis. It's The New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, why this moment is particularly urgent, and how we can best communicate that without screaming OMG PLEASE HELP over and over. We also touch on our history and how our nonprofit model makes Mother Jones different than most of the news out there: Letting us go deep, focus on underreported beats, and bring unique perspectives to the day's news.

You're here for reporting like that, not fundraising, but one cannot exist without the other, and it's vitally important that we hit our intimidating $390,000 number in online donations by June 30.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. It's going to be a nail-biter, and we really need to see donations from this specific ask coming in strong if we're going to get there.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate